دورية أكاديمية
أعرض في EDS

LncRNA LITATS1 suppresses TGF-β-induced EMT and cancer cell plasticity by potentiating TβRI degradation.

التفاصيل البيبلوغرافية
العنوان: LncRNA LITATS1 suppresses TGF-β-induced EMT and cancer cell plasticity by potentiating TβRI degradation.
المؤلفون: Fan C; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Wang Q; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Kuipers TB; Department of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands., Cats D; Department of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands., Iyengar PV; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Hagenaars SC; Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands., Mesker WE; Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands., Devilee P; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands., Tollenaar RAEM; Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands., Mei H; Department of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands., Ten Dijke P; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: The EMBO journal [EMBO J] 2023 May 15; Vol. 42 (10), pp. e112806. Date of Electronic Publication: 2023 Mar 30.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8208664 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2075 (Electronic) Linking ISSN: 02614189 NLM ISO Abbreviation: EMBO J Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024- : [London] : Nature Publishing Group
Original Publication: Eynsham, Oxford, England : Published for the European Molecular Biology Organization by IRL Press, [c1982-
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/metabolism , Lung Neoplasms*/metabolism , RNA, Long Noncoding*/genetics, Humans ; Cell Line, Tumor ; Cell Movement ; Cell Plasticity ; Epithelial-Mesenchymal Transition/genetics ; Transforming Growth Factor beta/metabolism ; Ubiquitin-Protein Ligases/genetics ; Receptor, Transforming Growth Factor-beta Type I
مستخلص: Epithelial cells acquire mesenchymal phenotypes through epithelial-mesenchymal transition (EMT) during cancer progression. However, how epithelial cells retain their epithelial traits and prevent malignant transformation is not well understood. Here, we report that the long noncoding RNA LITATS1 (LINC01137, ZC3H12A-DT) is an epithelial gatekeeper in normal epithelial cells and inhibits EMT in breast and non-small cell lung cancer cells. Transcriptome analysis identified LITATS1 as a TGF-β target gene. LITATS1 expression is reduced in lung adenocarcinoma tissues compared with adjacent normal tissues and correlates with a favorable prognosis in breast and non-small cell lung cancer patients. LITATS1 depletion promotes TGF-β-induced EMT, migration, and extravasation in cancer cells. Unbiased pathway analysis demonstrated that LITATS1 knockdown potently and selectively potentiates TGF-β/SMAD signaling. Mechanistically, LITATS1 enhances the polyubiquitination and proteasomal degradation of TGF-β type I receptor (TβRI). LITATS1 interacts with TβRI and the E3 ligase SMURF2, promoting the cytoplasmic retention of SMURF2. Our findings highlight a protective function of LITATS1 in epithelial integrity maintenance through the attenuation of TGF-β/SMAD signaling and EMT.
(© 2023 The Authors. Published under the terms of the CC BY NC ND 4.0 license.)
References: Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):. (PMID: 27449815)
Elife. 2022 Dec 29;11:. (PMID: 36579891)
Exp Cell Res. 2022 Apr 15;413(2):113024. (PMID: 35026283)
Nat Struct Mol Biol. 2015 Jan;22(1):5-7. (PMID: 25565026)
Int J Mol Sci. 2019 Jun 05;20(11):. (PMID: 31195692)
Commun Biol. 2019 Jul 24;2:272. (PMID: 31372511)
Trends Cell Biol. 2017 Sep;27(9):658-672. (PMID: 28552280)
FEBS Lett. 2006 May 22;580(12):2811-20. (PMID: 16678165)
Cell Death Dis. 2018 Jun 13;9(6):706. (PMID: 29899418)
Nature. 2014 Jan 16;505(7483):344-52. (PMID: 24429633)
Noncoding RNA Res. 2022 Feb 25;7(2):66-70. (PMID: 35310927)
Cancer Res. 2019 Jun 1;79(11):2821-2838. (PMID: 30952633)
J Biol Chem. 2015 Mar 13;290(11):6857-67. (PMID: 25605728)
Nature. 1997 Oct 9;389(6651):631-5. (PMID: 9335507)
Trends Cell Biol. 2019 Mar;29(3):212-226. (PMID: 30594349)
EMBO Rep. 2021 Jul 5;22(7):e50193. (PMID: 33960111)
Nat Commun. 2020 Feb 7;11(1):785. (PMID: 32034145)
Nat Methods. 2011 May 15;8(7):559-64. (PMID: 21572407)
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629. (PMID: 28397828)
Trends Cancer. 2017 Jan;3(1):56-71. (PMID: 28718426)
NPJ Vaccines. 2017 Oct 19;2:29. (PMID: 29263884)
Nat Commun. 2020 Oct 12;11(1):5127. (PMID: 33046716)
EMBO J. 2023 May 15;42(10):e112806. (PMID: 36994542)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Nat Methods. 2020 Jul;17(7):685-688. (PMID: 32572232)
PLoS One. 2013 Dec 18;8(12):e82241. (PMID: 24367507)
J Clin Lab Anal. 2021 Feb;35(2):e23651. (PMID: 33247856)
Breast Cancer Res Treat. 2012 Jul;134(1):219-27. (PMID: 22297469)
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. (PMID: 30459476)
Cancer Cell. 2014 May 12;25(5):666-81. (PMID: 24768205)
Cell Oncol (Dordr). 2021 Jun;44(3):595-609. (PMID: 33797737)
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560. (PMID: 31114875)
Oncogene. 2021 May;40(20):3578-3592. (PMID: 33931741)
EMBO J. 1998 Jun 1;17(11):3091-100. (PMID: 9606191)
Anticancer Res. 2015 Feb;35(2):1017-23. (PMID: 25667489)
Biomolecules. 2020 Mar 23;10(3):. (PMID: 32210029)
Cardiovasc Ther. 2020 May 06;2020:2016259. (PMID: 32528555)
Cancer Lett. 2021 Mar 31;501:162-171. (PMID: 33359709)
Cancer Sci. 2020 Aug;111(8):2672-2681. (PMID: 32485023)
Oncogene. 2018 Nov;37(48):6195-6211. (PMID: 30002444)
Adv Clin Exp Med. 2021 Apr;30(4):395-403. (PMID: 33857357)
J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204)
Nat Genet. 2013 Jun;45(6):580-5. (PMID: 23715323)
Nat Rev Genet. 2016 May;17(5):272-83. (PMID: 27040487)
Nucleic Acids Res. 2021 Jan 25;49(2):1173-1198. (PMID: 33398349)
Toxicology. 2021 Mar 15;451:152683. (PMID: 33482250)
Trends Cell Biol. 2018 Apr;28(4):287-301. (PMID: 29274663)
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2826-2832. (PMID: 30115383)
Phys Biol. 2019 Jan 18;16(2):021001. (PMID: 30560804)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Nat Commun. 2019 Jul 19;10(1):3246. (PMID: 31324771)
Sci Transl Med. 2018 Oct 10;10(462):. (PMID: 30305452)
Expert Opin Drug Deliv. 2019 Nov;16(11):1205-1226. (PMID: 31530041)
Int J Cancer. 2018 Nov 1;143(9):2213-2224. (PMID: 29761481)
Methods Mol Biol. 2022;2488:47-65. (PMID: 35347682)
Cell Rep. 2019 Sep 17;28(12):3182-3198.e11. (PMID: 31533040)
Signal Transduct Target Ther. 2022 Apr 29;7(1):126. (PMID: 35484112)
Sci Rep. 2019 Dec 30;9(1):20299. (PMID: 31889167)
Mol Cell Endocrinol. 2021 Jan 15;520:111064. (PMID: 33091558)
Clin Cancer Res. 2020 Mar 15;26(6):1460-1473. (PMID: 31857432)
Dev Cell. 2014 Apr 14;29(1):59-74. (PMID: 24735879)
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109. (PMID: 34527184)
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. (PMID: 32300252)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
RSC Adv. 2018 Mar 16;8(19):10582-10592. (PMID: 35540439)
Clin Chem. 2006 Jun;52(6):1089-95. (PMID: 16627561)
Mol Pharmacol. 2002 Jul;62(1):58-64. (PMID: 12065755)
Curr Opin Oncol. 2013 Jan;25(1):76-84. (PMID: 23197193)
J Vis Exp. 2017 Apr 25;(122):. (PMID: 28518096)
Nat Commun. 2013;4:2939. (PMID: 24326307)
Cell Cycle. 2020 Jan;19(2):218-232. (PMID: 31878829)
J Exp Clin Cancer Res. 2017 Apr 17;36(1):54. (PMID: 28412955)
Mol Cell. 2003 Apr;11(4):915-26. (PMID: 12718878)
Mol Cell. 2000 Dec;6(6):1365-75. (PMID: 11163210)
Nucleic Acids Res. 2013 Apr 1;41(6):e74. (PMID: 23335781)
Cell. 2020 Nov 25;183(5):1151-1161. (PMID: 33068526)
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118. (PMID: 33353982)
Cancer Cell. 2015 Mar 9;27(3):370-81. (PMID: 25759022)
Cell. 2008 Apr 4;133(1):66-77. (PMID: 18394990)
J Med Internet Res. 2021 Jul 26;23(7):e27633. (PMID: 34309564)
Trends Cancer. 2022 Feb;8(2):98-109. (PMID: 34872888)
World J Urol. 2016 Apr;34(4):485-93. (PMID: 26194612)
Acta Biochim Biophys Sin (Shanghai). 2018 Jan 1;50(1):37-50. (PMID: 29228156)
فهرسة مساهمة: Keywords: LINC01137; TGF-β type I receptor; ZC3H12A-DT; epithelial-mesenchymal transition; transforming growth factor-β
سلسلة جزيئية: GEO GSE203119; GSE198393
المشرفين على المادة: 0 (RNA, Long Noncoding)
EC 2.3.2.26 (SMURF2 protein, human)
0 (Transforming Growth Factor beta)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I)
تواريخ الأحداث: Date Created: 20230330 Date Completed: 20230516 Latest Revision: 20230525
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10183827
DOI: 10.15252/embj.2022112806
PMID: 36994542
قاعدة البيانات: MEDLINE
الوصف
تدمد:1460-2075
DOI:10.15252/embj.2022112806